# Wayrilz (rilzabrutinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rilzabrutinib

> The FDA approved Wayrilz (rilzabrutinib), sponsored by Sanofi (SNY), on August 29, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Wayrilz (rilzabrutinib) FDA approved?

Yes. The FDA approved Wayrilz (rilzabrutinib), sponsored by Sanofi (SNY), on August 29, 2025. FDA novel drug approvals: "Wayrilz | rilzabrutinib | 8/29/2025 | To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroidsDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/rilzabrutinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/rilzabrutinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Wayrilz (rilzabrutinib) |
| Codes | PRN1008, SAR444671 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Immune Thrombocytopenia](https://sec-api.dev/indications/immune-thrombocytopenia), [Graves' Disease](https://sec-api.dev/indications/graves-disease), [Focal Segmental Glomerulosclerosis](https://sec-api.dev/indications/focal-segmental-glomerulosclerosis), [Sickle Cell Disease](https://sec-api.dev/indications/sickle-cell-disease), [Immunoglobulin G4 Related Disease](https://sec-api.dev/indications/immunoglobulin-g4-related-disease), [Autoimmune Haemolytic Anaemia](https://sec-api.dev/indications/autoimmune-haemolytic-anaemia) |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### August 29, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2024-12-13, last confirmed 2025-08-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-24-278124): "Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312524278124/d913939dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-192215): "The target action date for the US FDA regulatory decision for ITP, which was granted fast track designation, is August 29, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525192215/d86864dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-136654): "The target action date for the FDA regulatory decision for ITP, which was granted fast track designation, is August 29, 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525136654/d81295dex991.htm
- FDA novel drug approvals: "Wayrilz | rilzabrutinib | 8/29/2025 | To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroidsDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

### August 29, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Wayrilz | rilzabrutinib | 8/29/2025 | To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroidsDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "NDA219685 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250829, review_priority STANDARD; sponsor_name GENZYME CORP; product WAYRILZ (RILZABRUTINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219685%22

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07216079

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07216079

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06500702

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06500702

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Graves' Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06984627

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Graves' Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06984627 (A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06984627

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Sickle Cell Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06975865

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Sickle Cell Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06975865 (The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-23 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06975865

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07007962

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immune Thrombocytopenia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07007962 (Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07007962

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Autoimmune Haemolytic Anaemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07086976 (A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07086976

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Autoimmune Haemolytic Anaemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07086976 (A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07086976

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Immunoglobulin G4 Related Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190196 (A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07190196

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Immunoglobulin G4 Related Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07190196 (A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-28 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07190196

## Same indication

- [Crizanlizumab](https://sec-api.dev/pdufa/crizanlizumab) (NVS)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Etavopivat](https://sec-api.dev/pdufa/etavopivat) (NVO)
- [Exa-cel](https://sec-api.dev/pdufa/exa-cel) (VRTX)
- [Exagamglogene autotemcel](https://sec-api.dev/pdufa/exagamglogene-autotemcel) (VRTX)
- [Experimental: yb-101](https://sec-api.dev/pdufa/experimental-yb-101) (YARW)
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab) (BIIB)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [INCA000585](https://sec-api.dev/pdufa/inca000585) (INCY)
- [Inclacumab](https://sec-api.dev/pdufa/inclacumab) (PFE)
- [Ndec - oral decitabine-tetrahydrouridine](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine) (NVO)
- [PCV21](https://sec-api.dev/pdufa/pcv21) (SNY)
- [Pociredir](https://sec-api.dev/pdufa/pociredir) (FULC)
- [Praliciguat (part a)](https://sec-api.dev/pdufa/praliciguat-part-a) (AKBA)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [December 2026](https://sec-api.dev/fda-calendar/2026-12), [February 2027](https://sec-api.dev/fda-calendar/2027-02), [July 2027](https://sec-api.dev/fda-calendar/2027-07), [November 2027](https://sec-api.dev/fda-calendar/2027-11), [May 2028](https://sec-api.dev/fda-calendar/2028-05), [June 2028](https://sec-api.dev/fda-calendar/2028-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rilzabrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Wayrilz (rilzabrutinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rilzabrutinib

```bibtex
@misc{secapidev_pdufa_rilzabrutinib_20261116,
  title        = {Wayrilz (rilzabrutinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rilzabrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rilzabrutinib_20261116","title":"Wayrilz (rilzabrutinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rilzabrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
